scholarly journals Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 272
Author(s):  
Jon Danel Solano-Iturri ◽  
Enrique Echevarría ◽  
Miguel Unda ◽  
Ana Loizaga-Iriarte ◽  
Amparo Pérez-Fernández ◽  
...  
Keyword(s):  
Renal Cell ◽  
Tumour Progression ◽  
Renin Angiotensin System ◽  
Staging System ◽  
Staining Intensity ◽  
Renal Oncocytoma ◽  
Angiotensin System ◽  
Promising Therapeutic Target ◽  
Renal Tumours ◽  
Grade Tumour

(1) Background: Renal cancer is one of the most frequent malignancies in Western countries, with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of reliable biomarkers of tumour progression. (Pro)renin receptor (PRR) is a novel receptor of the renin–angiotensin system (RAS) that has been associated with the development and progression of some solid tumours by RAS-dependent and -independent mechanisms. (2) Methods: In this study, we analysed the immunohistochemical expression of PRR at the centre and border in a series of 83 clear-cell renal cell (CCRCCs), 19 papillary (PRCC) and 7 chromophobe (ChRCC) renal cell carcinomas, and the benign tumour renal oncocytoma (RO, n = 11). (3) Results: PRR is expressed in all the tumour subtypes, with higher mean staining intensity in ChRCCs and ROs. A high expression of PRR at the tumour centre and at the infiltrative front of CCRCC tissues is significantly associated with high grade, tumour diameter, local invasion and stage, and with high mortality risk by UCLA integrated staging system (UISS) scale. (4) Conclusions: These findings indicate that PRR is associated with the development and progression of renal tumours. Its potential as a novel biomarker for RCC diagnosis/prognosis and as a promising therapeutic target should be taken into account in the future.

scholarly journals Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma

2016 ◽  
Author(s):  
Lisa Derosa ◽  
Hassane Izzedine ◽  
Laurence Albiges ◽  
Bernard Escudier
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Angiotensin Receptor Blockers ◽  
Treatment Options ◽  
Renin Angiotensin System ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitors ◽  
Angiotensin System

Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.

scholarly journals Altered Tissue and Plasma Levels of Fibroblast Activation Protein-α (FAP) in Renal Tumours

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3393
Author(s):  
Jon Danel Solano-Iturri ◽  
Peio Errarte ◽  
María C. Etxezarraga ◽  
Enrique Echevarria ◽  
Javier Angulo ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Renal Cell ◽  
Complex Disease ◽  
Fibroblast Activation Protein ◽  
Response To Therapy ◽  
Renal Oncocytoma ◽  
Renal Cell Carcinomas ◽  
Cancer Specific Survival ◽  
Fibroblast Activation ◽  
Renal Tumours

(1) Background: Renal cell carcinoma (RCC) is a heterogeneous and complex disease with only partial response to therapy, high incidence of metastasis and recurrences, and scarce reliable biomarkers indicative of progression and survival. Cancer-associated fibroblasts (CAFs) play an important role supporting and promoting renal cancer progression. (2) Methods: In this study, we analysed fibroblast activation protein-α (FAP) immunohistochemical expression and its soluble isoform (sFAP) in tumour tissues and plasma from 128 patients with renal tumours. (3) Results: FAP is expressed in the cell surface of CAFs of the tumour centre and infiltrating front from clear cell renal cell carcinomas (CCRCC, n = 89), papillary renal cell carcinomas (PRCC, n = 21), and chromophobe renal cell carcinomas (ChRCC, n = 8), but not in the benign tumour renal oncocytoma (RO, n = 10). A high expression of FAP and low levels sFAP are significantly associated with high tumour diameter, high grade, and high pT stage, lymph node invasion, development of early metastases, and worse 5-year cancer specific survival of CCRCC patients. (4) Conclusions: These findings corroborate the potential usefulness of FAP immunohistochemistry and plasma sFAP as a biomarker of CCRCC progression and point to CAF-related proteins as promising immunohistochemical biomarkers for the differential diagnosis of ChRCC and RO.

Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice

2015 ◽  
Vol 33 (9) ◽  
pp. 389.e1-389.e7 ◽  
Author(s):  
Wedson F. Araújo ◽  
Marcelo A. Naves ◽  
Juliana N. Ravanini ◽  
Nestor Schor ◽  
Vicente P.C. Teixeira
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renin Angiotensin System ◽  
Metastatic Potential ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals The role of the renin-angiotensin system in the appearance and progression of renal cell carcinoma: a literature review

2019 ◽  
Vol 15 (3) ◽  
pp. 143-149
Author(s):  
M. I. Kogan ◽  
Z. M. Akhokhov ◽  
E. A. Chernogubova ◽  
A. A. Gusev ◽  
Z. Kh. Oitova
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Mechanisms ◽  
Renin Angiotensin System ◽  
The Body ◽  
Molecular Medicine ◽  
Angiotensin System ◽  
Renin Angiotensin

Renal cell carcinoma (RCC) is one of the most common forms of malignant epithelial tumors of this localization. The development of new approaches to the diagnosis, prognosis and treatment of RCC is an topical issue of molecular medicine. The renin-angiotensin system (RAS) is not only an important component of the central and humoral mechanisms of controlling blood pressure and hydroelectrolytic balance, but also refers to the body systems involved in complex carcinogenesis pathways. Researches on the role of RAS in tumor progression are currently the priority. The data on the role of RAS in the development and progression of malignant tumors in the kidneys are being discussed. In this article, we present an overview of data on the role of RAS in the emergence and development of RCC, an analysis of the molecular mechanisms of development and progression of RCC, the prospects for using indicators of the RAS: angiotensin-converting enzymes (ACE), ACE2 and angiotensin II receptors as markers of diagnosis and monitoring of neoplastic transformation processes in the kidney. The prospects for the use of new, effective anticancer drugs with a targeted effect on definite indicators of the RAS of RCC were analyzed.

Sign in / Sign up

Export Citation Format

Share Document